We are live on ! Find out more
1.58 USD
+0.20
14.49%
At close Updated Nov 4, 4:00 PM EST
Pre-market
After hours
1.52
-0.06
3.8%
1 day
14.49%
5 days
11.27%
1 month
1.28%
3 months
-71.22%
6 months
-79.74%
Year to date
-77.75%
1 year
-84.18%
5 years
-90.69%
10 years
-94.36%
 

About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Employees: 223

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 6.3%
Neutral 90.6%
Negative 3.1%
Neutral
GlobeNewsWire
2 days ago
CVRx to Participate in Upcoming Investor Conferences
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences: Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m.
CVRx to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
13 days ago
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
Neutral
PRNewsWire
1 month ago
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Neutral
GlobeNewsWire
1 month ago
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
Neutral
GlobeNewsWire
1 month ago
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Neutral
GlobeNewsWire
1 month ago
CVRx Appoints John Landry as Chief Financial Officer
Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience
CVRx Appoints John Landry as Chief Financial Officer
Neutral
PRNewsWire
1 month ago
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Neutral
PRNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Neutral
GlobeNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Positive
Zacks Investment Research
2 months ago
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
CVRx Secures Devoted Health Coverage for Barostim Therapy
Price charts implemented using Lightweight Charts™